ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma



Status:Active, not recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:10/19/2018
Start Date:March 1, 2014
End Date:January 27, 2020

Use our guide to learn which trials are right for you!

A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination
with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory
multiple myeloma.

Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide
and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma


Inclusion Criteria:

- Must have a documented diagnosis of multiple myeloma and have relapsed-and-refractory
disease. Patients must have received at least 2 lines of prior therapies. Patients
must have relapsed after having achieved at least stable disease (SD) for at least one
cycle of treatment to at least one prior regimen and then developed progressive
disease (PD). Patients must also have documented evidence of PD during or within 60
days (measured from the end of the last cycle) of completing treatment with the last
anti-myeloma drug regimen used just prior to study entry (refractory disease)

- Must have undergone prior treatment with at least 2 cycles of lenalidomide and at
least 2 cycles of a proteasome inhibitor (either in separate regimens or within the
same regimen)

- Must not be a candidate for autologous stem cell transplant (ASCT), has declined the
option of ASCT, or has relapsed after prior ASCT

- Must have measurable levels of myeloma paraprotein in serum (≥ 0.5 g/dL) or urine (≥
0.2 g/24 hours)

- Must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1,
or 2

- Females of child bearing potential (FCBP) must have a negative serum or urine
pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to,
and again within 24 hours of starting pomalidomide and must either commit to continued
abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
control, one highly effective method and one additional effective method AT THE SAME
TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to
ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact
with a FCBP even if they have had a vasectomy. All patients must be counseled at a
minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control
Methods,and Education and Counseling Guidance must be followed per protocol

- Must be able to take acetylsalicylic acid (ASA) (81 or 325 mg) daily as prophylactic
anticoagulation. Patients intolerant to ASA may use low molecular weight heparin.
Lovenox is recommended. Coumadin will be allowed provided the patient is fully
anticoagulated, with an international normalized ratio (INR) of 2 to 3

Exclusion Criteria:

- Pregnant or lactating females

- Prior therapy with HDAC inhibitor

- Any of the following laboratory abnormalities:

- ANC < 1,000/µL

- Platelet count < 75,000/ µL for patients in whom < 50% of bone marrow nucleated
cells are plasma cells; and < 50,000/ µL for patients in whom ≥ 50% of bone
marrow nucleated cells are plasma cells

- Hemoglobin < 8g/dL (<4.9 mmol/L; prior red blood cell [RBC] transfusion is
permitted)

- Creatine clearance < 45mL/min according to Cockcroft-Gault formula. If creatine
clearance calculated from the 24-hour urine sample is ≥ 45 mL/min, patient will
qualify for the study

- Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST),
or serum glutamic pyruvic transaminase (SGPT)/ alanine aminotransferase (ALT) >
3.0 × ULN

- Serum total bilirubin > 2.0 mg/dL

- Prior history of malignancies, other than MM, unless the patient has been free of the
disease for ≥ 3 years. Exceptions include the following:

- Basal or squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix or breast

- Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)

- Corrected QT interval using Fridericia's formula (QTcF) value > 480 msec at screening;
family or personal history of long QTc syndrome or ventricular arrhythmias including
ventricular bigeminy; previous history of drug-induced QTc prolongation or the need
for treatment with medications known or suspected of producing prolonged QTc intervals
on electrocardiogram (ECG)

- Positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis
C virus (HCV) infection

- Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (such as Steven
Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is
allowable

- Peripheral neuropathy ≥ Grade 2 despite supportive therapy

- Radiotherapy or systemic therapy (standard or an investigational or biologic
anticancer agent) within 14 days of initiation of study drug treatment

- Current enrollment in another clinical trial involving treatment and/or is receiving
an investigational agent for any reason

- Inability or unwillingness to comply with birth control requirements or regional
REMS/RevAid programs
We found this trial at
16
sites
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Calgary, Alberta
?
mi
from
Calgary,
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Hawthorne, New York 10532
?
mi
from
Hawthorne, NY
Click here to add this to my saved trials
Hawthorne, New York 10532
?
mi
from
Hawthorne, NY
Click here to add this to my saved trials
Lafayette, Indiana 47905
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials